Boehringer Ingelheim Pharmaceuticals, Inc.
NEWS
Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
Three companies have posted major developments in the field of heart disease therapy.
It was another busy week for clinical trial news. Here’s a look.
The U.S. FDA greenlit a new indication for Gilead Sciences’ drug Biktarvy for pediatric patients with HIV who are virologically suppressed or new to antiretroviral therapy.
The European Society for Medical Oncology Congress 2021 runs from September 16–21, 2021. Here’s a preview of some of the presentations at the meeting.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
JOBS
IN THE PRESS